Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated